Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...

Shantanu Gaur, the founder and chief executive of Allurion, said the goal of the study would be to prove that combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy would ...

James Manning / PA Images via Getty Images Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves ...

The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less™ gastric balloon for weight loss with the ...

The company plans to evaluate its Allurion Program with GLP-1 agonists to address muscle loss concerns and promote healthier weight loss. Allurion entered into a securities purchase agreement to ...

by combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy, patients can lose significant weight while increasing muscle mass and improving overall body composition.

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity Allurion Technologies, Inc. (“Allurion” or the “Company ...

NATICK, Mass., January 21, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today ...

Allurion Technologies, Inc. (ALUR) a Massachusetts-based medical device company Tuesday announced the issuance of a new U.S. patent ...